Refractory Kawasaki Disease With a Giant Aneurysm Successfully Treated With Infliximab and Enoxaparin: A Case Report.

IF 2.5 4区 医学 Q2 HEALTH POLICY & SERVICES
Zhe-Jia Liu, Wan-Fu Hsu
{"title":"Refractory Kawasaki Disease With a Giant Aneurysm Successfully Treated With Infliximab and Enoxaparin: A Case Report.","authors":"Zhe-Jia Liu, Wan-Fu Hsu","doi":"10.1016/j.pedhc.2024.09.001","DOIUrl":null,"url":null,"abstract":"<p><p>Kawasaki disease (KD) is the most common vasculitis in children, and can result in the development of coronary artery aneurysms (CAAs) if not properly managed. While intravenous immunoglobulin (IVIG) and aspirin are standard first-line treatments, refractory KD may develop, increasing the risk of coronary complications. Herein, we report the case of a young girl with KD who initially responded to IVIG, but later developed a giant CAA, despite additional treatments. Infliximab stabilized her condition, and one year later, the CAA remained stable without thrombus formation. This case demonstrates that clinical appearance, particularly fever, may not fully reflect the patient's condition, as fever can subside immediately after treatment, but may relapse days later, underscoring the need for vigilant monitoring.</p>","PeriodicalId":50094,"journal":{"name":"Journal of Pediatric Health Care","volume":" ","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pediatric Health Care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.pedhc.2024.09.001","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH POLICY & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Kawasaki disease (KD) is the most common vasculitis in children, and can result in the development of coronary artery aneurysms (CAAs) if not properly managed. While intravenous immunoglobulin (IVIG) and aspirin are standard first-line treatments, refractory KD may develop, increasing the risk of coronary complications. Herein, we report the case of a young girl with KD who initially responded to IVIG, but later developed a giant CAA, despite additional treatments. Infliximab stabilized her condition, and one year later, the CAA remained stable without thrombus formation. This case demonstrates that clinical appearance, particularly fever, may not fully reflect the patient's condition, as fever can subside immediately after treatment, but may relapse days later, underscoring the need for vigilant monitoring.

用英夫利昔单抗和依诺肝素成功治疗伴有巨大动脉瘤的难治性川崎病:病例报告。
川崎病(KD)是儿童中最常见的血管炎,如果处理不当,可能导致冠状动脉瘤(CAA)的发生。静脉注射免疫球蛋白(IVIG)和阿司匹林是标准的一线治疗方法,但也可能出现难治性 KD,从而增加冠状动脉并发症的风险。在此,我们报告了一例患有 KD 的年轻女孩的病例,她最初对 IVIG 有反应,但后来出现了巨大的 CAA,尽管接受了其他治疗。英夫利西单抗稳定了她的病情,一年后,CAA 仍保持稳定,没有血栓形成。该病例表明,临床表现,尤其是发热,可能并不能完全反映患者的病情,因为发热可能在治疗后立即消退,但几天后又可能复发,这就强调了警惕监测的必要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.40
自引率
10.70%
发文量
140
审稿时长
24 days
期刊介绍: The Journal of Pediatric Health Care, the official journal of the National Association of Pediatric Nurse Practitioners, provides scholarly clinical information and research regarding primary, acute and specialty health care for children of newborn age through young adulthood within a family-centered context. The Journal disseminates multidisciplinary perspectives on evidence-based practice and emerging policy, advocacy and educational issues that are of importance to all healthcare professionals caring for children and their families.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信